Home » Stocks » DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc. (DMPI)

Stock Price: $1.29 USD 0.11 (8.90%)
Updated Aug 11, 2020 12:25 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 14.72M
Revenue (ttm) n/a
Net Income (ttm) -7.89M
Shares Out 11.46M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $1.29
Previous Close $1.18
Change ($) 0.11
Change (%) 8.90%
Day's Open 1.23
Day's Range 1.20 - 1.33
Day's Volume 1,202,841
52-Week Range 0.38 - 2.45

More Stats

Market Cap 14.72M
Enterprise Value 9.75M
Earnings Date (est) Sep 23, 2020
Ex-Dividend Date n/a
Shares Outstanding 11.46M
Float 10.64M
EPS (basic) -1.42
EPS (diluted) -0.95
FCF / Share -0.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 211,710
Short Ratio 0.32
Short % of Float 1.40%
Beta 1.85
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.02
Revenue n/a
Operating Income -8.28M
Net Income -7.89M
Free Cash Flow -7.16M
Net Cash 4.97M
Net Cash / Share 0.43
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -136.86%
ROE -316.72%
ROIC 638.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(133.46% upside)
Current: $1.29
Target: 3.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-8.40-11.17-8.32-6.21-4.72
Net Income-8.05-11.14-8.08-8.86-4.35
Shares Outstanding2.572.
Earnings Per Share-3.16-5.42-7.40-8.30-4.60
Operating Cash Flow-6.33-9.85-8.02-5.15-3.85
Free Cash Flow-6.33-9.85-8.02-5.15-3.85
Cash & Equivalents3.725.976.596.161.75
Net Cash / Debt3.725.976.596.161.75
Book Value1.975.446.584.86-0.82
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name DelMar Pharmaceuticals, Inc.
Country United States
Employees 2
CEO Saiid Zarrabian

Stock Information

Ticker Symbol DMPI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DMPI


DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.